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maging Stem Cells Implanted in Infarcted Myocardium
ong Zhou, PHD,* Paul D. Acton, PHD,‡ Victor A. Ferrari, MD†
hiladelphia, Pennsylvania
Stem cell–based cellular cardiomyoplasty represents a promising therapy for myocardial
infarction. Noninvasive imaging techniques would allow the evaluation of survival, migration,
and differentiation status of implanted stem cells in the same subject over time. This review
describes methods for cell visualization using several corresponding noninvasive imaging
modalities, including magnetic resonance imaging, positron emission tomography, single-
photon emission computed tomography, and bioluminescent imaging. Reporter-based cell
visualization is compared with direct cell labeling for short- and long-term cell
tracking. (J Am Coll Cardiol 2006;48:2094–106) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.026Cardiology Foundation
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Eoronary heart disease accounts for 36% of all cardiovascu-
ar death and is the leading cause of heart failure in the U.S.
1). Although post-infarction survival rates have been im-
roved in recent years, cardiac dysfunction due to segmental
oss of ventricular mass remains a major problem (2). In fact,
rogressive left ventricular remodeling occurs in between
ne third to one half of survivors of acute myocardial
nfarction with ejection fractions 40% (3), despite optimal
edical therapies, none of which is able to effectively reverse
he detrimental remodeling process (4). Even when im-
lantable cardioverter-defibrillators are used, 5-year mortal-
ty from ischemic cardiomyopathies exceeds 35% (5). Al-
hough cardiac transplantation is the most effective therapy,
he disparity between organ demand and supply limits its
pplicability. A novel treatment strategy often referred to as
cellular cardiomyoplasty” includes local (intramyocardial,
ntracoronary) and systemic (intravenous) delivery of fetal/
eonatal cardiomyocytes (6,7), skeletal myoblasts (8–10),
mbryonic stem cells (11,12), bone marrow-derived mesen-
hymal stem cells (BMSCs) (13–19), or hematopoietic stem
ells (20–22). This strategy attempts to enhance cardiac
unction by repopulating the infarcted region with viable
ardiomyocytes and, therefore, bears great promise for
estoration of ventricular function after infarction beyond
hat achievable with current medical therapy (23).
More than 6 phase I clinical trials have been conducted
sing skeletal myoblasts (24) (for review, see Menasche
25]); these trials identified a proarrhythmic risk associated
ith myoblast implantation and required implantation of an
nternal cardioverter-defibrillator in patients participating in
From the *Departments of Radiology and †Medicine (Cardiovascular), University
f Pennsylvania, and ‡Department of Radiology, Thomas Jefferson University,
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r. Zhou) and by the Pennsylvania State Department of Health Tobacco Block
rant (to Dr. Zhou).c
Manuscript received June 20, 2006; revised manuscript received August 14, 2006,
ccepted August 14, 2006.he ongoing MAGIC (Magnesium in Coronaries) trial.
linical trials using bone marrow cells have demonstrated the
afety and feasibility of the procedure but have yielded mixed
esults in terms of therapeutic benefit (Table 1). Although
ignificant improvement of cardiac function has been doc-
mented in a few trials (26–29), results from 4 double-
linded randomized and placebo-controlled trials are not as
romising, either showing moderate (30), short-term ben-
fits (31), or no improvement (32,33). Attempts to mobilize
ematopoietic stem cells (CD34) from the bone marrow
y granulocyte-colony stimulating factor also yielded am-
iguous results. Whereas a small-scale FIRSTLINE-AMI
Front-Integrated Revascularization and Stem Cell Libera-
ion in Evolving Acute Myocardial Infarction by Use of
ranulocyte-Colony-Stimulating Factor) trial showed im-
rovement of left ventricular function (27), negative results
ere obtained from a large-scale double-blinded random-
zed and placebo-controlled trial, REVIVAL (Regenerate
ital Myocardium by Vigorous Activation of Bone Marrow
tem Cells) (34). Issues such as selection of low-risk
atients (35) and microvasculature obstruction have been
roposed to explain the negative results. However, the
limination of infused cells from the heart might have been
primary culprit. Studies showed that less than 3% of
nfractionated bone marrow cells were retained in the
nfarcted heart within a few hours after intracoronary
nfusion (36). Both cell type and delivery route (i.e., intra-
oronary, intramyocardial, or intravenous) have been shown
o affect the retention of cells in the heart (36,37). Unfrac-
ionated bone marrow cells used in many trials contain
arious cell populations, some of which may have adverse
ffect on cardiac repair (38). Critical issues raised from these
linical trials that need to be addressed include 1) the fate of
ngrafted cells and optimization of cell survival; 2) the
ptimal cell type; and 3) mechanisms of action (25,38–41).
xperts in the field questioned whether sufficient pre-linical data have been gleaned to understand pharmacoki-
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November 21, 2006:2094–106 Tracking Stem Cells by Imagingetics, pharmacodynamics, and mechanism to provide the
ype of solid support on which clinical trials are built (38).
maging-based cell-tracking methods can potentially evalu-
te the short-term distribution of infused cells (discussed in
he direct labeling method section) or their long-term
urvival (discussed in the reporter gene approach section)
nd cardiac differentiation status (see the section “Optical
maging”). Therefore, these methods would play an indis-
ensable role in detailed preclinical studies to optimize the
ell type, delivery methods, and strategies for enhancing cell
urvival. Safety and ethical issues imposed on a human study
ould limit the clinical translation of those methods that
equire extensive manipulation of cells; however, most direct
abeling methods discussed in the sections “Magnetic Res-
able 1. Clinical Trials Using Autologous Bone Marrow Cells
Clinical Trial Name
(Reference)
Patients
(n)
OPCARE-AMI (26,28) 20 Significant
MI pati
STAMI* (33), preliminary results (30) 100 No improv
months
OOST* (31) 60 No improv
patients
TEMI* (32) 66 No improv
function
IRSTLINE-AMI (27) 30 G-CSF–in
LVEF a
G-CSF
EVIVAL* (34) 114 G-CSF–in
size, LV
G-CSF
EPAIR-AMI* preliminary results (30) 204 A 3% imp
infusion
ACT (29) 18 Significant
chronic
mononu
Abbreviations and Acronyms
BMSC  bone marrow-derived mesenchymal stem cell
D2R  dopamine type 2 receptor
ECFP  enhanced cyan fluorescent protein
Fluc  firefly luciferase
GFP  green fluorescent protein
HSV1-tk  herpes simplex virus type 1 thymidine kinase
MLC2v  ventricular myosin light chain 2
MPIO  micrometer-sized superparamagnetic iron
oxide
NIS  sodium-iodide symporter
PET  positron emission tomography
SPECT  single-photon emission computerized
tomography
SPIO  superparamagnetic iron oxide
TA  transfecting agent
TFR  transferrin receptor
TK  thymidine kinase
USPIO  ultrasmall superparamagnetic iron oxideDenotes double-blinded, randomized, and placebo-controlled trials.
FDG  fluoro-2-deoxy-D-glucose; G-CSF  granulocyte colony-stimulating factor; Lnance Imaging” and “Radionuclide Imaging” have already
pplied in patients or would be suitable for the clinic.
A number of methods are available to visualize cells; in
eneral, they can be divided into 2 categories: 1) the direct
abeling method and 2) the reporter gene approach. The
ormer involves using an imaging-detectable probe that can
e loaded into cells and would remain intracellular during
racking. This method does not involve extensive manipu-
ation of the cells and, therefore, is preferred for clinical
mplementation. It has 2 inherent limitations: labels may be
iluted upon cell division, making these cells invisible; and
abels may efflux from cells or may be degraded over time.
herefore, this method is suitable for short-term tracking to
nswer the question: “Where do the cells go?” and may
llow monitoring of second or third delivery of cells when
revious labels disappear. For clinical application, the pri-
ary issue is to identify suitable labels that are safe to cells
ven when the intracellular label accumulates to a high
oncentration. Contrast media or agents that already have
een approved for clinical use, such as 2-[F-18]-fluoro-2-
eoxy-D-glucose for positron emission tomography (PET)
36), [In-111]oxine for single-photon emission computer-
zed tomography (SPECT) (42,43), and superparamagnetic
ron oxide (SPIO) particles for magnetic resonance imaging
MRI) (43), are among the first being tested in various
linical trials of cell tracking.
For preclinical applications, in addition to direct labeling,
he reporter gene approach is used. This approach involves
nserting a reporter gene(s) into stem cells for the purpose of
racking. Products of reporter gene expression generally can
e divided into 3 categories, enzymes, receptors, or trans-
orters. Diagrams in Figs. 1A to 1C illustrate how these 3
eporters work for radionuclide imaging modalities.
Major Findings
ovement of LVEF and regional wall motion in the infarct zone in acute
t 4 months after infusion of bone marrow or blood-derived progenitors.
ts of LV function compared with controls in acute MI patients at 6
infusion of cells.
t of LV systolic function compared with the controls in acute MI
months after intracoronary infusion of cells.
t in LVEF in acute MI patients with relatively well-preserved cardiac
months after injection of cells.
mobilization of mononuclear CD34 cells led to improvement in
evention of LV remodeling in acute MI patients at 12 months after
ent.
mobilization of mononuclear CD34 cells had no influence on infarct
tion, or coronary restenosis in acute MI patients at 4 to 6 months after
ent.
ent in LVEF over controls in acute MI patients at 4 months after
lls.
ovement in LVEF and increased FDG uptake in the infarcted region in
atients at 3 months after intracoronary injection of bone marrow
cells.impr
ents a
emen
after
emen
at 18
emen
at 4
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clearVEF  left ventricular ejection fraction; MI  myocardial infarction.
t
g
t
u
b
a
t
g
w
F
t
d
m
w
s
c
t
t
S
d
d
c
M
S
n
g
u
u
c
d
d
d
a
d
a
s
S
c
a
p
m
t
p
F
F
t
F
M
w
w
t
m
p
(
r
f
C
2096 Zhou et al. JACC Vol. 48, No. 10, 2006
Tracking Stem Cells by Imaging November 21, 2006:2094–106To prevent loss of the reporter upon cell division, a stable
ransfection, that is, integration of the reporter gene into cell
enome, is necessary; thus, extensive molecular manipula-
ion is required (44). Reporter genes would be extremely
seful in assessing survival status of the implanted cells
ecause the reporter will be expressed as long as the cells are
live and will be passed to daughter cells upon cell division;
his approach has been used to monitor the uncontrolled
rowth of embryonic stem cells into a tumor (teratoma)
hen a large number of cells are implanted, as shown in
igure 1D. If a cardiac specific promoter is used to control
he expression of the reporter (46,47), then the cardiac
ifferentiation of stem cells in their physiological environ-
ent also can be monitored. The reporter gene approach
ould allow selection for optimal cell type and engraftment
ites that promote survival or differentiation of implanted
ells.
This review describes methods for cell tracking based on
heir corresponding imaging modalities: MRI, radionuclide
omographic imaging techniques focusing on PET and
PECT, and optical imaging. For each imaging modality,
irect labeling methods as well as reporter gene approaches are
iscussed, in addition to their utility in clinical and preclinical
igure 1. Diagrams of detection of (A) enzyme-based (e.g., herpes simple
ype 2 receptor [D2R]), and (C) transporter-base (e.g., sodium-iodide sym
-18–labeled tracers or by single-photon emission tomography using I-123
edica). In A, 9-[3-fluoro-1-hydroxy-2-(propoxymethyl)]guanine tracers t
hereas unbound ones will diffuse out of cells. In B, tracers binding to D2
ill be washed out. In C, tracers will be transported into and out of cells
hrough organification (see the section “Radionucleotide Imaging” for de
illion (107) murine embryonic stem cells transfected with a truncated vers
ositron emission tomography was performed at day 4 and weeks
propoxymethyl)]guanine was injected intravenously for visualization of H
eceiving cells, but control animals had background activities only. Quantifi
rom week 2 to week 4, corresponding to proliferation of embryonic stem c
ao et al. [45] with permission).ell tracking applications. iAGNETIC RESONANCE IMAGING
uperparamagnetic iron oxide particles. Superparamag-
etic iron oxide particles are well known for their ability to
enerate MR contrast. For diagnostic MRI, 2 acronyms are
sed for iron-based magnetic particles: SPIO particles and
ltra-small SPIO (USPIO) particles; both consist of a
rystalline iron oxide core coated with polymers such as
extran, polyethylene glycol, and starch; SPIOs, with a hydro-
ynamic diameter 30 nm, are taken up by the reticuloen-
othelial system in the liver and spleen, leading to remark-
ble signal loss in these tissues. The USPIOs (30 nm
iameter) can escape the initial uptake by liver and spleen
nd reach other targets, such as lymph nodes (48), and can
erve as a blood pool agent (49). They are obtained from
PIOs by size exclusion or other fractionation procedures;
ompared with SPIOs, USPIOs have lower T2 relaxivities
nd longer blood half life, both as the result of their smaller
article size. Synthesis of SPIO and USPIO particles, their
agnetic properties (e.g., relaxivities) and clinical applica-
ions are reviewed recently by Lawaczeck et al. (50).
Two compounds within the SPIO family have been ap-
roved for clinical use: one compound under the name of
eridex (Berlex Biosciences, Ricmond, Virginia; or ferumox-
type 1 thymidine kinase [HSV1-tk]), (B) receptor-based (e.g., dopamine
r [NIS]) reporter genes detected by positron emission tomography using
inted from Acton and Zhou [44] with permission from Edizioni Minerva
e bound and metabolized by the HSV1-TK will be trapped inside the cells,
cell surface will contribute to the imaging signal, whereas unbound ones
S; cells from nonthyroid tissues, however, cannot retain the iodine inside
(D) In vivo assessment of cell survival and proliferation over time. Ten
f HSV1-tk were injected into the myocardium of a noninfarcted nude rat;
, 3, and 4. Approximately 1 mCi [F-18]9-[3-fluoro-1-hydroxy-2-
-tk–expressing cells. Positive signal was observed at week 1 in animals
n of imaging signals showed a drastic increase of thymidine kinase activity
to intracardiac and extracardiac tumors, that is, teratoma (reprinted fromvirus
porte
(repr
hat ar
R on
by NI
tails).
ion o
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November 21, 2006:2094–106 Tracking Stem Cells by Imaginghe name of Resovist (or SH-U555A; Schering, Berlin, Ger-
any) in Europe and Japan. Both compounds are manufac-
ured for intravenous administration and are targeted at (met-
static) tumors in the liver and spleen.
Besides their role in clinical diagnostic imaging, SPIOs
nd USPIOs have become a useful tool for cell tracking in
he brain (51–53), heart (15,54–56), and other organs
57,58). A recent clinical trial in European Union demon-
trated for the first time in humans tracking of therapeutic
endritic cells labeled with Feridex (43). Although it rep-
esents a clinically applicable method to label cells using
eridex or other SPIOs approved for clinical imaging (59),
his approach will require U.S. Food and Drug Adminis-
ration approval. Furthermore, when injected intravenously,
eridex or other SPIOs is primarily taken up by the
eticuloendothelial system (e.g., Kupffer cells), which me-
abolizes the excess iron; nonphagocytic stem cells, however,
ay not have this capability; therefore, effects of iron
verloading on stem cell proliferation and differentiation
hould be investigated before the clinical application of
eridex or other SPIOs.
Endocytosis is a major mechanism for intracellular uptake
f SPIO particles into various types of cells such as T cells
60) and macrophages (61). Transfection agents (TAs) such
s poly-L-lysine (59), cationic liposome (62), or protamine
ulfate (63) forms complexes with SPIO particles in the
abeling solution and greatly improve the efficiency of
ndocytosis in cells that cannot avidly phagocytose SPIOs.
n addition, these agents seemed to protect the cells from
PIO particles, which otherwise were found to be toxic to
onphagocytic cells at high concentrations (62). Other ways
o enhance endocytosis-mediated intracellular accumulation
f SPIO particles include covalent conjugation of SPIOs to
ntibodies or to cell penetrating peptides such as HIV
ransactivator (tat) peptide (58,64) or proteins (65).
ntibody-linked SPIOs enter into cells via receptor-
ediated endocytosis (57,66) whereas an adsorptive endo-
ytosis (67) is thought to mediate the uptake of tat peptide-
onjugated SPIOs. Metabolic fate of SPIO particles are
xpected to be similar after endocytosis-mediated uptake.
s demonstrated in the case of SPIO-TA complexes, after
eing endocytosed, they are localized to endosomes (68,69),
hich are later fused with lysosomes, where the SPIO is
egraded (68). The long-term viability, growth and apopto-
ic indexes of Feridex-TA–labeled human BMSCs were
ound unaffected as compared with the unlabeled cells (70).
owever, it is controversial over whether the differentiation
f BMSCs was affected by SPIO particles or by the type of
A used: it has been shown that chondrogenesis of BMSCs
as inhibited by Feridex-poly-L-lysine labeling (71) but not
y Feridex-protamine labeling (72). No studies on effects of
PIO labeling on cardiac differentiation of stem cells have
een reported so far.
In addition to endocytosis, the electroporation procedure
73) has been investigated to achieve instant intracellular
elivery of SPIOs, therefore eliminating the need for cransfection agents, conjugating antibodies and peptides and
ell culture procedures all together. Because the SPIO
articles are directly internalized to cytoplasm but not
nsulated in membrane vesicles such as endosomes, their
etabolic fate may not be the same as those being endocy-
osed.
Recently, micrometer-sized SPIO (MPIO) particles (1
o a few micrometers in diameter) have been proposed for
ore sensitive detection and have been investigated in a
umber of preclinical studies. These particles contain20%
o 60% magnetite by weight and are made by a special
rocess whereby a mixture of magnetite and polystyrene/
ivinyl benzene is dispersed in water, and the suspension is
olymerized to trap the magnetite in the polymer matrix;
he magnetite is dispersed throughout the beads. Initially
eveloped for magnetic cell separation (74), MPIO particles
re approximately 35-fold larger in diameter and more than
0,000 times larger in volume than the USPIOs; by far,
hese particles have the highest sensitivity for MRI detec-
ion (17,69,75,76).
The detectability of labeled cells depends on a number of
actors, including magnetic field strength, how much iron
ccumulates inside each cell (labeling efficiency), the num-
er of cells implanted, relaxivity of the IO particle, and
patial resolution of the image. Feridex-labeled stem cells
ere readily detected by MRI when 107 to 108 stem cells
ach containing approximately 16 pg of Fe (59) were
njected directly into myocardium of a swine as demon-
trated in Figures 2A and 2B, reprinted from Kraitchman
t al. (15). For stem cells labeled with MPIO particles, an
fficiency of 0.2  0.18 ng iron oxide per cell (equivalent to
43  130 pg Fe per cell) was reported by Hill et al. (77);
ote that cellular iron oxide content in this work is indirectly
uantified through fluorescence label of the particle; detec-
ion of 105cells implanted into a pig heart was reported at a
.5-T scanner as shown in Figure 2C, reprinted from Hill et
l. (77).
Using SPIO labels, the detection of a small number of
ells or single cells by MRI has been achieved in the rat and
ouse brain (53,78,79). In contrast, detection of single or
mall numbers of cells in the heart by MRI is an even
reater challenge because of cardiac motion and limited
ntracellular concentration of imaging probes. For T2/T2*-
ased MRI detection, the signal loss at the boundary of
eart and lung as the result of susceptibility difference also
ould pose an interference as demonstrated in Figure 2D:
he T2* values of the lateral myocardium wall were very close
o those of labeled cells at the injection site. Injections
erformed under X-ray, NOGA cardiac mapping system, or
R guidance will ensure the mid-myocardium location of
mplanted cells; however, potential cell migration or wall
hinning may push these cells in close proximity to the
picardial side of the lateral wall.
erritin and transferrin receptor. Although iron is an
ndispensable participant in numerous physiological pro-
esses and biochemical reactions in the body such as
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Tracking Stem Cells by Imaging November 21, 2006:2094–106ransportation of oxygen in the blood, free iron ions are
oxic to cells, and the body has an elaborate set of mecha-
isms to bind iron in various tissue compartments. Ferritin
s such a metalloprotein and is found mainly in the liver,
hich can store approximately 4,500 iron ions in a hollow
hell made of 24 identical subunits. Ferritin genes have been
roposed as a reporter gene for MRI detection: through
ransfection by an adenoviral vector, overexpression of
erritin genes inside cells leads to intracellular iron accumu-
ation and MR contrast as the result of shortening of T2/T2*
80,81).
Transferrin is a plasma protein for iron transport. Each
ransferrin molecule has the ability to carry two iron ions
Fe3) and is taken up by a transferrin receptor (TFR) on
he cell surface; consequently, iron molecules are trans-
orted inside the cell. An engineered TFR (82,83) has been
roposed as a reporter gene; this TFR gene expresses an
pproximate 5-fold excess of transferrin receptors on the cell
urface and lacks the iron regulatory region; therefore, TFR
xpression is not regulated by intracellular iron concentra-
ion; for TFR overexpressing cells to accumulate sufficient
ron for imaging, transferrin proteins are covalently linked
o USPIO particles and the complex is injected intrave-
ously; gradient echo MRI then detects the signal loss (as
he result of T2/T2* decrease) induced by uptake of
ransferrin-USPIO by cells overexpressing TFR. Compared
ith the ferritin reporter system, the requirement for cova-
ent attachment of USPIOs to transferrin is cumbersome
ut increases the detection sensitivity because of the larger
article size of USPIOs compared with ferritin. Iron over-
oading due to the overexpression of a mutated TFR that
acks the iron regulatory region may disrupt cellular metab-
lism, leading to toxicity as evidenced by elevated reactive
xygen species level in the cell (84). The feasibility of using
erritin and the TFR reporter system for cell tracking in the
ouse brain at 1.5-T and 7-T magnetic field strength has
ecently been investigated (84).
adolinium chelates. In contrast to the negative image
ontrast (hypointensity) generated by USPIO/SPIO/MPIO
articles by T2/T2* mechanism, gadolinium III [Gd(III)]
igure 2. Detection using magnetic resonance imaging (MRI) at 1.5 T,
yocardium of a swine; MRI was performed 24 h after injection. (B) Mag
15] with permission). (C) Detection using MRI at 1.5 T of micrometer-
mplanted in the myocardium of a swine (reprinted from Hill et al. [77] w
cale immediately to the right; T2* values of micrometer-sized superparam
t the heart/lung boundary. Obviously, the reduction of T2* at myocardiu
entricle; RV  right ventricle.roduces positive contrast (enhancement) on T1-weighted cR images. Although the relaxivity is very similar among
he various small molecular Gd(III) chelates currently in
linical use, they differ in 2 structural features: ionic versus
onionic and linear versus macrocyclic (85), for example,
dDTPA (Magnevist; Berlex Biosciences) is a linear and
onic chelate, whereas gadoteridol (ProHance; Bracco-Byk
ulden, Konstanz, Germany) is a nonionic and macrocyclic
helate. Because of their relatively low longitudinal relaxiv-
ty (4 mmol l1s1), high intracellular accumulation is the
ey for the utility of these contrast media as labeling agents.
t has been estimated that the number of internalized
d(III) chelates on the order of 107 to 108 per cell is
ecessary for MRI visualization of cells (86). The structural
eatures mentioned previously may determine their ability to
enetrate the cell membrane and potential toxicities to the
ells exposed to high concentrations during incubation. As
he result of the nonparticulate nature of the Gd chelates,
inocytosis (used by cells for absorption of extracellular
uids) instead of phagocytosis would be a major mechanism
or their cellular uptake; recent studies show that pinocytosis
ppears to be a very effective way for labeling stem cells by
ncubating cells with high concentrations of Gd(III) che-
ates for a period of a few hours (87). Compared with
inocytosis, which is a form of endocytosis (88) and in
hich Gd(III) chelates are sequestered in membrane vesi-
les, electroporation procedure results in intracellular distri-
ution of Gd molecules and a greater longitudinal relaxation
ate constant (R1) and higher MR signal intensity of labeled
ells compared with pinocytosis (89). A class of macrocyclic
anthanide chelates has been synthesized that label cells by
nserting 2 hydrophobic alkyl chains into cell membranes
ith the hydrophilic metal binding site facing the extracel-
ular medium (90). By association only with the cell mem-
ranes, these labels are unlikely to be metabolized by cellular
nzymes that lead to release of toxic free Gd ions; further-
ore, Gd chelate is more accessible by extracellular water
esulting in a higher relaxivity.
-19 – based labeling agents. In addition to the nuclei of
-1, some other nuclei, including F-19, P-31, and C-13
lso have MR phenomena and can be detected; the multinu-
ridex-labeled mesenchymal stem cells (107 to 108 cells) injected into the
tion of view inside the yellow box in A (reprinted from Kraitchman et al.
superparamagnetic iron oxide–labeled mesenchymal stem cells (105 cells)
rmission). (D) The color map corresponds to T2* values indicated on the
c iron oxide–labeled cells are very close to those of lateral myocardial wall
air interface is a source of interference for detection of cells. LV  leftof Fe
nifica
sized
ith pe
agneti
m andlear capability is usually included in research scanners
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November 21, 2006:2094–106 Tracking Stem Cells by Imagingor spectrometers); for clinical scanners, capability of nu-
leus other than H-1 is also available as optional packages.
he gyromagnetic ratio of F-19 nuclei is approximately 90%
f the proton; therefore, it is a sensitive nucleus for MR
etection; furthermore, there is no background F-19 signal
ecause F-19 is not a natural metabolite in mammals. The
natomical localization of the F-19 signal is achieved by
verlaying F-19 images on H-1 images acquired sequen-
ially. F-19-based compounds such as perfluoropolyether
ave been used for tracking dendritic cells in animals (91).
reliminary results on F-19 MR imaging of stem cells
abeled with perfluoro-nanoparticles are promising (92,93).
ADIONUCLIDE IMAGING
ecause of their exquisite picomolar (1011 to 1012 mol/l)
ensitivity (94), PET and SPECT imaging modalities are
ble to detect tracer quantity of radioisotopes for studying
iological processes in living subjects. Technological devel-
pments of both PET and SPECT have led to the imple-
entation of specialized systems for small animal imaging
ith much greater spatial resolution (1–2 mm) (95–103),
hich has dramatically advanced the field of cell tracking in
nimal models in vivo.
adioisotope-based cell labels. Radioactive isotopes such
s [In-111]oxyquinoline (oxine) (42) and [T-99m]
examethylprophylene amine oxime (104) have been used in
he nuclear medicine clinic for labeling autologous white
lood cells, which are subsequently infused back to the
atients for localization of inflammatory sites. In general,
adioisotopes with a relatively long decay half-life are used
o track cells during a period of several hours or even days,
igure 3. (A) In vivo single-photon emission computed tomography (SPE
dual-energy window detects simultaneously Tc-99m (pseudo-colored in
agnetic resonance image (grey) (reprinted from Shen et al. [113] with k
f heart slices obtained after In-111 and Feridex double-labeled stem cells
f iron for localization of stem cells (reprinted by permission of the So
n-111–labeled bone marrow–derived mesenchymal stem cells to infarcted
PECT imaging is shown. For each panel, sagittal (left) and coronal (right)
f cells in the lung is indicated by strong In-111 signal in the lung (reprinted fr
ight ventricle.or instance In-111 (T1/2  2.8 days) for SPECT and
u-64 (T1/2  12.7 h) for PET (105). The isotope is
arried into the cells via a lipophilic chelator, which governs
he initial extraction of the tracer into the cells. Once inside
he cells, a trapping mechanism reduces the lipophilicity
f the molecule, and the isotope is retained. After a short
ncubation period, the cells are washed to remove any
nbound activity and are injected into the host. Labeling
fficiencies close to 100% are not uncommon, although
ellular concentrations of the isotope depend on factors,
ncluding cell type, incubation time, and concentrations. For
ell tracking in the heart, [In-111]oxine (106–110), [In-
11]tropolone (111), [Tc-99m]exametazime (112), and
F-18]fluoro-2-deoxy-D-glucose (36) have been used. The
iodistribution of In-111-labeled stem cells after intrave-
ous (106), intramyocardial, intracoronary, and interstitial
etrograde coronary venous delivery has been reported (37):
t was found that most delivered cells were not retained in
he heart for each delivery modality, which raised the
oncern that proangiogenic or other physiological effects
onveyed by these cells may have a negative impact on
issues or organs that are not the target of these cells.
A dual isotope SPECT study of In-111-labeled cardio-
yoblasts and [Tc-99m]sestamibi enabled the imaging of
oth cells and perfusion deficit in the infarcted region
imultaneously (109); the SPECT images were registered
ith the high-resolution MR images, which provides de-
ailed myocardial anatomy for localization of cells, as shown
n Figure 3A (113); the autoradiographic confirmation of
n-111 signal with the histological staining of stem cells are
resented in Figures 3B to 3D. As a step further from
imaging of In-111–labeled stem cells implanted in the infarcted rat heart;
w) and In-111 (blue) signals; the SPECT images were coregistered on a
ermission of Springer Science and Business Media). (B) Autoradiographs
mplanted in the infarcted heart of a rat; (C and D) Prussian blue staining
of Nuclear Medicine from Zhou et al. [109]). (E and F) Homing of
(dog) after intravenous injection at day 1 (E), day 2 (F) and day 7 (G) by
of fused SPECT (color) and CT (grey) images are shown. Initial retentionCT)
yello
ind p
were i
ciety
heart
viewom Kraitchman et al. [110] with permission). LV  left ventricle; RV 
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Tracking Stem Cells by Imaging November 21, 2006:2094–106etection of a large number of cells implanted in the heart,
he monitoring of stem cell homing using SPECT has been
chieved in small animals using a Gamma camera (108) and
n large animals using a clinical SPECT scanner (110). As
hown in Figures 3E to 3G, after being doubly labeled by
n-111 and Feridex, BMSCs were intravenously injected
nto a dog model, and their homing to the heart was
etected by the use of SPECT; however, the use of MRI
as not able to detect these small numbers of cells.
lthough the minimal number of In-111-labeled cells that
an be detected in the heart in vivo is not known, a recent
tudy using phantom suggested that 10,000 cells could be
etected in a 16-min scan with appropriate background
orrection (111).
One concern of radioactive labeling agents is the potential
adiation damage to the cell as demonstrated in a study in
hich hematopoietic progenitor cells were labeled with
In-111]oxine and injected into the cavity of the left
entricle heart in a rat model of myocardial infarct (108);
lthough gamma imaging revealed homing of the progeni-
or cells to infarcted myocardium, significant impairment of
roliferation and function of labeled cells was observed. A
ecent study by Jin et al. (111) comparing In-111 incubation
ctivity and cell viability at day 14 suggests that 100%
iability can be achieved provided the incubation activity is
0.9 MBq.
Rapid efflux of labels out of cells over the course of time
105,109) leads to label loss from viable cells. In a SPECT
tudy using [In-111]oxine-labeled cardiomyoblasts (109),
ne third of the original In-111 signal was obtained 72 h
fter injection when corrected for radio decay of In-111.
abel loss introduces errors to the detection of surviving
ells because one cannot distinguish whether reduction of
n-111 signal is due to loss of labels from viable cells or is
ue to death or remove of cells from the injection site.
herefore, the direct labeling approach is more suitable for
he short-term tracking of injected cells whereas a reporter
ene approach, discussed next, would allow monitoring of
urvival of implanted cells over a longer period of time.
eporter genes for PET/SPECT detection. A number of
eporter genes have been developed for PET and SPECT
maging (44,114). Herpes simplex virus type 1 thymidine
inase (HSV1-TK) or its mutant form HSV1-sr39tk (115)
xpresses a viral thymidine kinase (note that tk represents
he gene whereas TK represents the protein). Thymidine
inase phosphorylates a range of substrates, including thy-
idine (the natural substrate), analogs of pyrimidine, and
cycloguanosines. The monophosphates resulted from TK
eaction are converted by cellular enzymes to di- and
riphosphates, which are trapped inside the cells, as
hown in Figure 1A; in contrast, cells not expressing TK
ill not metabolize or retain the tracer. A variety of
yrimidine analogs and acycloguanosine derivatives, e.g.,
-[3-Fluoro-1-hydroxy-2-(propoxymethyl)]guanine
FHBG), have been designed for better tracer retention and
etection by PET and SPECT imaging of HSV1-tk ex- bression (see review by Tjuvajev et al. [116]). The metab-
lites of TK, if present at a sufficiently high concentration,
esult in cell death; therefore, HSV1-tk has been used as a
uicide gene in many gene therapy protocols (117–119) or as
negative selection marker to eliminate TK-expressing cells
n standard molecular biology protocols. By taking advan-
age of the high sensitivity of PET or SPECT imaging
odalities, it is possible to administer tracer quantities of
he substrate labeled with a positron or single-photon
mitting radioisotope for detection of HSV1-tk expression
nd, as such, toxicity to TK-expressing cells should be
egligible: the feasibility of utilizing HSV1-tk as a reporter
instead of a suicide) gene has been demonstrated (120–
27). HSV1-tk reporter gene has been examined in preclin-
cal studies for evaluations of gene therapy directed at the
yocardium (128,129).
The concept of reporter gene is applicable to cell tracking.
urviving cells can be tracked when a promoter of viral
rigin (e.g., the promoter of cytomegalovirus [CMV]) is
sed to control the expression of the reporter gene; such a
eporter gene is constitutively active as long as the cell is
live and is minimally regulated by physiological processes
n the cell. Positron emission tomograpic imaging detection
f cardiomyoblasts (H9c2 cells) that are transiently trans-
ected with CMV-HSV1-tk and were subsequently injected
nto rat myocardium has been demonstrated (130). How-
ver, to monitor the survival or proliferation of implanted
ells over the course of time, it is necessary to stably
ntegrate the reporter gene into genomes of implanted cells.
table transfection will ensure that the reporter will not be
iluted upon cell division (45). However, the reporter
rotein, when it is of exogenous origin and is exposed
utside cells, may induce immune reactions from the host,
eading to elimination of reporter signals.
Dopamine type 2 receptor (D2R) is a receptor-based
eporter gene and is one of the few systems that could be
sed for cell tracking in the brain because the reporter
robe, for instance, [F-10]fluoroethylspiperone (FESP),
eadily crosses the intact blood-brain barrier. It binds to the
2R with high affinity and has been shown to provide a
uantitative measure of D2R expression in living animals
131). To overcome the potential problems that the occu-
ancy of the ectopic D2R by the endogenous agonist may
ncrease levels of cellular cyclic adenosine monophosphate
cAMP), leading to physiologic consequences on the target
issue/cells (132), mutant strains of the D2R that do not
ctivate the signal pathway have been developed for PET
maging (133). In the brain, the presence of endogenous
2R, particularly in the striatum, would provide a large
ackground signal and make it difficult to resolve the
resence of the D2R reporter system. A similar problem
ay apply to the myocardium, in which expression of a
etectable level of D2R is reported (134).
The sodium-iodide symporter (NIS), as shown in Figure
C, has been proposed as a reporter gene (135–137) and has
een applied to cardiac imaging (138,139). The NIS occurs
n
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November 21, 2006:2094–106 Tracking Stem Cells by Imagingaturally in high concentrations in the thyroid, with lower
oncentrations in salivary glands, stomach, thymus, breast,
nd other tissues. The symporter is a membrane glyco-
rotein and provides an active transport mechanism for
odium and iodine ions into cells. The expression of the
ymporter can be imaged with radioactive iodine, such as
-123 for SPECT or I-124 for PET, or other tracers, which
ind to the same site, such as [Tc-99m]pertechnetate. A
road range of cell types and delivery mechanisms have been
sed with the NIS reporter. The NIS is not immunogenic,
nd its endogenous expression is limited to a few tissues,
llowing it to be used in a variety of imaging applications.
owever, the use of NIS as a reporter system has been
ampered somewhat by the efflux of the radiotracers from
onthyroid tissues. In the thyroid, organification of the
odine occurs, catalyzed by the enzyme thyroperoxidase,
hich effectively traps the iodine after it is transported into
he tissue. Coexpression of this enzyme with the NIS
eporter gene may be required to improve the retention of
adioactive iodine in transfected cells (140).
An additional benefit of the reporter gene approach is the
ossibility of linking a therapeutic gene to the reporter,
llowing the system to monitor both cell trafficking and
ene therapy simultaneously (141). For example, skeletal
yoblasts have been used to deliver a therapeutic gene, such
s vascular endothelial growth factor, which may aid in the
ormation of new vessels in the region being regenerated by
he grafted myoblasts (142). Coupling a reporter gene to
tem or progenitor cells would allow tracking of not only cell
elivery and survival, but also the expression of the thera-
eutic gene.
A major disadvantage of reporter gene approaches for cell
racking is the requirement for molecular manipulations of
he cells under study. When a virus or a viral vector is used
or transfection, immune reactions may be induced as a
esult of the expression of viral proteins or even the reporter
rotein itself when nonmammalian proteins, such as HSV1-tk,
re used, leading to loss of long-term expression of the reporter.
entiviral vector is preferred for stable integration of re-
orter genes into stem cells because it can transfect both
ividing and nondividing cells and lead to high levels of
ransgene expression (143,144). Other potential concerns
egarding long-term efficacy of the method include reporter
ene silencing, in which reporter gene expression decreases
ver time with progressive cell differentiation. Lentiviral
ectors (145) and certain pharmacologic interventions (146)
ave been proven to reduce the gene silencing problem.
PTICAL IMAGING
uminescence and fluorescence. Two optical imaging
echniques, luminescence and fluorescence, have been used
or stem cell tracking in vivo (147–151). Luminescence in
he form of light (wave length in the range of 400–700 nm)
s generated from an enzymatic reaction catalyzed by, e.g.,
refly luciferase (Fluc); when cells expressing Fluc are pupplied with D-luciferin, a substrate of the enzyme, cells
ill emit luminescence. Although weak, this light energy
an be captured by a sensitive charge-coupled device camera
n a light-sealed box. In addition to Fluc, other luciferases,
uch as Renilla luciferase with its substrate, coelenterazine,
ave also been utilized as reporter system (152,153). Be-
ause of limited tissue penetration of luminescence and the
act that luciferase is a nonmammalian protein, this imaging
odality is limited to small animal models. In addition,
uminescence detection relies on a continuous wave tech-
ique (154), leading to a diffusive image on the animal
urface, unlike PET/SPECT/MR imaging modalities, in
hich data are acquired in a tomographic fashion. Still,
uminescence imaging is extremely useful for high-
hroughput screening because of its high sensitivity and its
traightforward imaging procedures. Increasing the amount
f substrate (e.g., D-luciferin) for an enzymatic reaction
e.g., catalyzed by Fluc) will increase the amount of the
roduct (e.g., luminescence) even when the concentration of
he enzyme (Fluc) remains the same; therefore, the detec-
ion threshold of the luciferase reporter system can be
ignificantly reduced by administering an excess amount of
-luciferin, which does not appear to be toxic to animals
ven in large doses.
Fluorescence is generated by excitation of a fluorophore;
reen fluorescent protein (GFP) and its variants are the
ost commonly used optical reporters. Tomographic detec-
ion of fluorescence is feasible; however, because of high
hoton absorbance and scattering in the visible range, only
ear infrared (700 nm) fluorophores can be detected when
ocated a few centimeters underneath the surface. Shallow
enetration is a severe limitation for in vivo detection even
n small animals, not to mention in humans. Attachment of
fluorophore to a stem cell would allow detection of stem
ells by histology using conventional microscopes. Further
evelopments in optical imaging techniques, such as quan-
um dots (155), diffuse optical tomography (156,157), and
ptical coherence tomography (158), offer tremendous en-
ancements to currently available technology; their applica-
ions, however, are primarily limited to preclinical re-
earches.
tem cell differentiation monitored by cardiac-specific
eporter genes. A reporter gene permits longitudinal mon-
toring of fundamental biological processes (e.g. differenti-
tion) within the context of physiologically authentic envi-
onments. Monitoring of cardiac differentiation of stem
ells by reporter genes is made possible when the reporter is
xpressed as a consequence of a cardiac specific gene
xpression. In practice, this monitoring is achieved by using
romoter sequence of the cardiac gene to drive the expres-
ion of the reporter, rendering the latter under the tran-
criptional control of the former. Promoters of ventricular
yosin light chain 2 (MLC2v) and cardiac alpha myosin
eavy chain gene have been used to convey cardiac speci-
city to reporter genes (159,160). Meyer et al. (46) used the
romoter sequence of MLC2v gene to drive the expression
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Tracking Stem Cells by Imaging November 21, 2006:2094–106f enhanced cyan fluorescent protein (ECFP, a variant of
FP); when stem cells are transduced with MLC2v-ECFP
eporter, their cardiac differentiation as determined by
xpression of MLC2v gene was found to be parallel to the
etection of ECFP fluorescence (46). Cardiac specific GFP
eporter (or its variants) would be extremely useful for
creening or selection of stem cells undergoing cardiac
ifferentiation by fluorescent microscopy or flowcytometry
161). To monitor stem cells undergoing cardiac differen-
iation in vivo, luminescent (e.g., Fluc) or NIS reporter
nder cardiac specific promoters would be suitable; in vivo
uminescent imaging of MLC2v-Fluc expression in the
ouse heart has been achieved (47), suggesting that this
pproach is feasible for monitoring cardiac differentiation of
tem cells in small animals. Gamma camera and micro-PET
maging of cardiac alpha myosin heavy chain–NIS expres-
ion in the heart in a transgenic mouse model has been
emonstrated recently (139); this reporter gene is more
elevant to clinical application than Fluc because of the
onimmunogenic nature of NIS and the availability of
linical counterparts of the imaging modalities.
ENSITIVITY AND SPATIAL
ESOLUTION: MULTIMODALITY APPROACH
ell tracking demands high sensitivity and spatial resolution
rom imaging modalities because of the microscopic targets,
hat is, stem cells. It is generally thought that optical
maging has the greatest sensitivity: the detectable concen-
ration of the tracer ranges from 1015 to 1017 mol/l; this
s followed by PET and SPECT imaging (1011 to 1012
ol/l) whereas MRI is thought to have the lowest sensitivity
105 mol/l) (94). The concentration-based sensitivity as-
umes the target size is comparable with the image resolu-
ion: a 1-cm resolution (equivalent to 1000 l voxel size) is
ommon for a clinical PET scanner whereas submilimeter
esolution (voxel size ranging from 1 l to 103 l)
outinely is obtained on a clinical MRI scanner. When a
mall number of cells or single cells are the target, the
maging probe is concentrated in a small volume fraction of
voxel; as such, the aforementioned assumption is no longer
alid. An estimation of detection limit that includes the
ontribution of spatial resolution recently was proposed by
eyn et al. (79,162) and leads to the conclusion that the
etectability of SPIO-labeled single cells would be similar to
icro-PET detection of a few hundred cells labeled with
Cu-64]pyruvaldehyde-bis(N4-methylthiosemicarbazone).
owever, to the best of our knowledge, detection of a single
r a small number of stem cells in the heart has not been
eported likely because of various technical challenges dis-
ussed in the section “Super Paramagnetic Iron Oxide
articles.” Recent results on detection of MPIO-labeled
acrophages that were homed to the heterotypically trans-
lanted heart (76) shed promising light on this issue.
A multimodality reporter system expressing a trifusionrotein consisting of red fluorescent protein, Renilla lucif- vrase, and the HSV1-TK enzyme (153) offers the possibility
f using the particular imaging technique that best suits the
pplication: fluorescence for microscopy of cells or for cell
orting in vitro, bioluminescence for high sensitivity imag-
ng in vivo in small animals, and PET or SPECT when
uantitative accuracy is important, or tomographic localiza-
ion is necessary. The use of multiple imaging modalities
ould take advantage of high-detection sensitivity provided
y optical and radionuclide imaging and, at same time,
uperior spatial resolution afforded by MRI or other high-
esolution modalities (e.g., CT). The feasibility of localiza-
ion of stem cells detected by highly sensitive PET or
PECT imaging to the anatomical context described by
RI has been demonstrated in Figure 3A and also in
igures 3E to 3G, in which monitoring of stem cells
oming to the heart has been demonstrated using a multi-
odality approach to achieve high detection sensitivity and
igh spatial resolution. Because in vivo imaging also plays a
ignificant role in evaluation of cardiac functions, for exam-
le, global and regional contractile functions, perfusion, and
iability, multimodality imaging would combine stem cell
racking with evaluation of functional recovery resulted from
ellular cardiomyoplasty.
onclusions. The clinical promise for stem cell therapy in
schemic heart disease will not be fully attained without an
mproved understanding of stem cell biology and mecha-
isms of repair and regeneration. Early work in cardiac
ellular therapy has focused on more fundamental topics,
ncluding assessing stem cell survival and optimizing im-
lantation techniques; however, rigorous hypothesis testing
nd clinical applications will rely heavily on noninvasive
maging techniques to guide these investigations. The
evelopment of imaging tools that allow serial assessment of
he subject with high spatial resolution and the ability to
ontemporaneously determine cellular viability represent
ne of the current goals for these applications. Optical
maging techniques provide high spatial resolution and
ermit tracking of stem cells but are limited to preclinical
se. Nuclear techniques, including reporter genes and direct
ellular radiolabeling, afford very good detectability but
ore limited spatial resolution. Magnetic resonance imag-
ng methods permit good spatial resolution but limited
etectability. A multimodality approach using combined
ET or SPECT and MRI agents may ultimately prove
ost useful in clinical settings.
In the September 21, 2006 issue of the New England
ournal of Medicine, the results of 3 clinical trials involving
tem cell therapy for myocardial infarction were released.
he studies reported variable results with respect to im-
rovement in left ventricular function following cellular
herapy. In the Schachinger et al. (163) study, a statistically
ignificant—but clinically minimal—benefit in ventriculo-
raphic ejection fraction measurement was seen in the group
reated with bone marrow cells at 4 months post-therapy.
he ASATAMI trial (164) showed no improvement in leftentricular ejection fraction following injection of bone
m
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November 21, 2006:2094–106 Tracking Stem Cells by Imagingarrow cells, however, infarct size was reduced, and re-
ional wall motion was improved in the treatment group. In
he TOPCARE-CHD trial (165), there was a small (2.9%)
mprovement in left ventricular ejection fraction, but the
atients in this study had a history of remote, rather than
cute, infarctions which makes the findings even more
ignificant. These reports underscore the need for a greater
nderstanding of the mechanisms underlying stem cell
iology and cellular reparative therapy, and their potential
ses in the post-infarction state.
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